MedTrace Logo

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

NCT00467987 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2024-02-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the effects of testosterone deficiency in men with diabetes on atherogenesis, inflammation, cardiovascular Risk factors And adiposity .

Conditions

  • Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism

Interventions

DRUG

androgel

androgel 1%

DRUG

placebo

placebo

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    collaborator INDUSTRY

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Paresh Dandona · Kaleida Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
31 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-01
Primary Completion
2018-03-01
Completion
2018-10-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467987 on ClinicalTrials.gov